Research Feed

TDI-178 1/27/12 - This trophin was added as a new lead to the TDI pipeline.
TDI-177 1/27/12 - TDI added this small molecule compound as a new lead to its pipeline.
TDI-176 1/27/12 - This small molecule targeting the complement pathway was added as a new lead at TDI
TDI-175 1/27/12 - TDI added this small molecule targeting RNA metabolism as a new lead.
TDI-174 1/27/12 - TDI added this small molecule targeting RNA metabolism as a new lead.
TDI-173 1/27/12 - TDI added this small molecule immunmodulatory compound as a new lead.
TDI-172 1/27/12 - TDI added this small molecule immunmodulatory compound as a new lead.
TDI-169 1/20/12 - Small molecule targeting oxidative stress became a new lead.
TDI-0148 1/20/12 - This small molecule targeting RNA metabolism began in vitro testing at TDI
TDI-0114 (FK506) 1/20/12 - TDI removed this immunmodulatory small molecule from its pipeline
TDI-162 1/20/12 - TDI began in vitro validation experiments on this small molecule targeting unfolded protein response
TDI-167 12/19/11 - This compound targeting CD40L was added to our pipeline (collab with Biogen and UCB)

ALS TDI Research Center

What's happening at the #1 ALS research institute in the world? We're testing therapeutics faster and more cost-effectively than anyone else. In fact, we've tested more potential therapeutics than the rest of the ALS research world combined. We work urgently and in collaboration with international biotechnology and pharma companies, academic centers, and other disease organizations to accomplish our mission: to end ALS.